Mack Roach III, MD

Education

Morehouse College, Atlanta, GA, BS, 1975, Physics
Stanford University School of Medicine, Stanford,CA, MD, 1979, Medicine
University of California San Francisco, Fellow, 1981-83, Med Oncology
Stanford University School of Medicine, Stanford,CA, Resident, 1984-87, Radiation Oncology

Honors & Awards

• 1980-1981
  Outstanding Intern of the Year (Charles R. Drew Award)
• 1981-1982
  Fellow of the American Cancer Society
• 1994
  UCSF Health Net Wellness Award
• 1994-1997
  American Cancer Society Career Development Award
• 1996-97; 1997-98; 2001-02
  "The Best Doctors in America"
• 2002
  Fellow, American College of Radiology
• 2002-05
  President, John Hale Medical Society
• 2005
  10 Most Influential African Americans in the Bay Area (Healthcare)

Selected Publications

1. Mohamad O, Roach M Radiation Delay Is Okay, But Where Is the Evidence?  View on PubMed
2. Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF Considering benefit and risk before routinely recommending SpaceOAR.  View on PubMed
3. Chen WC, Li Y, Lazar A, Altan A, Descovich M, Nano T, Ziemer B, Sudhyadhom A, Cunha A, Thomas H, Gottschalk A, Hsu IC, Roach M Stereotactic body radiotherapy and high-dose rate brachytherapy boost in combination with intensity modulated radiotherapy for localized prostate cancer: a single-institution propensity score matched analysis.  View on PubMed
4. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CAF Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.  View on PubMed
5. Hsu IC, Rodgers JP, Shinohara K, Purdy J, Michalski J, Roach M, Vigneault E, Ivker RA, Pryzant RM, Kuettel M, Taussky D, Gustafson GS, Raben A, Sandler HM Long-term results of NRG Oncology/RTOG 0321 a phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate.  View on PubMed
6. Mohamad O, Roach M Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer.  View on PubMed
7. Gartrell BA, Roach M, Retter A, Sokol GH, Del Priore G, Scher HI Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer.  View on PubMed
8. Roach M Editorial Comment.  View on PubMed
9. Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G, Schaeffer E, Roach M, Evans CP, Hussain M Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.  View on PubMed
10. Han HJ, Li YR, Roach M, Aggarwal R Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.  View on PubMed
11. Li YR, Roach M The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging.  View on PubMed
12. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M, Spratt DE Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.  View on PubMed
13. Griffin RJ, Ahmed MM, Amendola B, Belyakov O, Bentzen SM, Butterworth KT, Chang S, Coleman CN, Djonov V, Formenti SC, Glatstein E, Guha C, Kalnicki S, Le QT, Loo BW, Mahadevan A, Massaccesi M, Maxim PG, Mohiuddin M, Mohiuddin M, Mayr NA, Obcemea C, Petersson K, Regine W, Roach M, Romanelli P, Simone CB, Snider JW, Spitz DR, Vikram B, Vozenin MC, Abdel-Wahab M, Welsh J, Wu X, Limoli CL Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy.  View on PubMed
14. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.  View on PubMed
15. Li YR, Roach M Re: Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.  View on PubMed
16. Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.  View on PubMed
17. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.  View on PubMed
18. Li YR, Roach M Stampede to Cure.  View on PubMed
19. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.  View on PubMed
20. Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Cl  View on PubMed

Go to UCSF Profiles, powered by CTSI